Biofourmis announced that it has raised $300 million in a Series D round, surpassing a $1 billion valuation, reports Home Health Care News.
The investment round was led by growth equity firm General Atlantic. CVS Health and existing investors also participated.
Biofourmis was originally founded in Singapore, and the company’s U.S. offices are headquartered out of Boston. The company leverages software and data science, along with clinical care teams, to deliver care virtually in the home. Read more.
